Clarient

Recently XIFIN sat down with Clarient CEO Ron Andrews and VP Finance Glen Fredenberg to discuss Clarient's experience with the XIFIN system. Hear what they had to say

Clarient at a Glance

Description: Clarient combines diagnostic technologies with pathology expertise to assess and characterize cancer. Clarient's mission is to become the leader in cancer diagnostics by dedicating itself to collaborative relationships with the healthcare community to translate cancer discovery and research into better patient care. Clarient's principal customers include pathologists, oncologists, hospitals, and biopharmaceutical companies. Clarient also develops and markets new, proprietary "companion" diagnostic markers for therapeutics in breast, prostate, lung, ovarian, and colon cancers, and leukemia/lymphoma.

In December 2010, GE Healthcare, a unit of General Electric Company (NYSE:GE), purchased Clarient, Inc. at an aggregate cash purchase price of approximately $570 million.

Website: www.clarientinc.com
Location: Aliso Viejo, CA
Phone: 949.425.5700
2010 Revenues: ~$110M